Latest news with #UniversalImmunizationProgramme
Time of India
11 hours ago
- Health
- Time of India
What is RSV and why are infants especially at risk in India?
Respiratory Syncytial Virus, commonly known as RSV, is the leading cause of respiratory illness in children and infants worldwide. In India, RSV has also become a major issue for parents as well as pediatricians, particularly in the post-monsoon and winter seasons when cases surge. Although the nation continues to establish complete surveillance information, existing studies in tertiary care facilities show that RSV contributes 30% to 50% of bronchiolitis and pneumonia incidents in children aged two years and below. RSV is usually responsible for the symptoms of a cold in older children and adults. Nevertheless, in infants—especially those under six months of age, those who were premature at birth, or those with underlying health issues—the virus may cause severe lower respiratory tract infections, including bronchiolitis (inflammation of small airways) and pneumonia. These two diseases usually require hospitalization, and hospitalization rates between 3 and 5 per 100 infants less than one year of age per year have been estimated in India. The risks are not equal throughout the nation. Geographic and socioeconomic variations account for both the risk of and outcome of RSV infection. Children living in lower-income populations or in densely populated urban environments can have increased exposure from lesser access to healthcare, suboptimal ventilation, and slower diagnosis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video] getfittoday Undo Seeing the international burden of RSV, the World Health Organization (WHO) recently supported maternal RSV vaccination as a prevention approach. This entails immunizing pregnant women so that antibodies are passed on to the unborn child, providing immunity in the vulnerable early months of life. Although not yet included in India's Universal Immunization Programme (UIP), Indian health authorities, such as the Indian Academy of Pediatrics, are in the process of evaluating the vaccine's safety, effectiveness, and affordability in India. Phased introduction in high-risk groups could be the initial step. Apart from vaccines, monoclonal antibodies too have been promising in the prevention of RSV-related complications. These provide passive immunity in a single dose of injection. But the big constraint is cost. Without government incentives or being covered under public health schemes, these therapies could prove to be out of reach for the majority of Indian families. Differential pricing models and collaborations with insurance companies will become paramount in order to expand access. More encouragingly, Indian drug makers are not idle either. Bharat Biotech and Serum Institute of India have initiated RSV research programs and are likely to bank on their experience in the production of pediatric and maternal vaccines. Tie-ups with global firms can also open the way for local production of monoclonal antibodies, leading to costs savings as well as wider availability. Experts put wide availability of RSV vaccines and antibodies in India at least 2 to 4 years down the road. Early access could start in corporate or private hospitals dealing with high-risk pregnancies. In the private sector, however, the incorporation of RSV prevention in the national immunization program will be crucial to making RSV vaccines and antibodies accessible and beneficial for all Indian infants—irrespective of birthplace. Article courtesy: Dr. Shreya Dubey - Consultant - Neonatology & Paediatrics, CK Birla Hospital, Gurugram Russia's Lavrov Sounds Alarm Over German Army Buildup Plan; 'Very Worrying, Need To…' One step to a healthier you—join Times Health+ Yoga and feel the change
Time of India
3 days ago
- General
- Time of India
Medical conclave urges stronger push for gender-neutral HPV vaccine for boys
Pune: Boys, along with girls, must be vaccinated against Human Papillomavirus (HPV), doctors at the launch of the "Conquer HPV & Cancer Conclave 2025" last week said. Panelists said that govt backs vaccination for girls under the Universal Immunization Programme (UIP), but boys and men, who are carriers of the virus, are equally affected by HPV and cancer-causing HPV and hence must also be vaccinated. Speakers emphasised that HPV is not limited to cervical cancer alone. It is also associated with cancers of the sexual organs, affecting both men and women. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential. Medical director of Bharati Vidyapeeth Medical College & Hospital Dr Sanjay Lalwani, who anchored the panel discussion, said the indigenous vaccine, Cervavac, is effective, safe and affordable. He added, "It is a gender-neutral vaccine and boys must also get vaccinated. While women can be screened regularly through a pap smear test, as of now men do not have any screening programme. So, boys between the age of 9 and 14 years must also be vaccinated, just like girls." Vaccination can protect partners from HPV-related cancers in adult life. There is no specific way to test directly for HPV in men that is approved for clinical use. The American Sexual Health Association has observed that men are typically screened clinically with a visual inspection to check for lesions such as warts. While still not routinely done, anyone with a history of receptive anal sex may want to speak with his or her healthcare provider about having an anal pap test, the association said. Dr Meenu Agarwal, secretary-general of International Society of Gynaecological Endoscopy, said, she sees young girls and women with genital warts and cervical cancer cases. "Now, when we go to the root of the problem, we realize that it is a sexually transmitted disease and that is the reason we need to vaccinate both boys and girls because we need to take care of the source of the spread." The rationale is to prevent different types of cancers that can occur in men as well, Dr Shirish Kankariya, former president of Indian Academy of Paediatrics, said. Parag Deshmukh, executive director, Serum Institute of India said, "Conclaves across the country will help increase understanding of Human Papillomavirus (HPV) and its link to cervical and other cancers." The conclave is part of a nationwide public health initiative led by the institute. 77k Cervical Cancer Deaths India bears a significant burden of HPV-related diseases, particularly cervical cancer, the second most common cancer among women in the country According to the ICO/IARC Information Centre on HPV and Cancer (2023), India reports over 1.23 lakh new cervical cancer cases and more than 77,000 related deaths, annually Up to 90% of anal cancers & 63% of penile cancers are associated with HPV
